Compare SAMG & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SAMG | WHWK |
|---|---|---|
| Founded | 2002 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.1M | 95.2M |
| IPO Year | 2013 | N/A |
| Metric | SAMG | WHWK |
|---|---|---|
| Price | $14.86 | $2.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 46.8K | ★ 168.6K |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | ★ 5.61% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $125,322,000.00 | $14,384,000.00 |
| Revenue This Year | $3.44 | N/A |
| Revenue Next Year | $9.39 | N/A |
| P/E Ratio | $20.84 | ★ N/A |
| Revenue Growth | ★ 4.23 | N/A |
| 52 Week Low | $13.23 | $1.39 |
| 52 Week High | $19.04 | $3.81 |
| Indicator | SAMG | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 53.70 | 57.36 |
| Support Level | $14.48 | $2.30 |
| Resistance Level | $15.53 | $2.63 |
| Average True Range (ATR) | 0.48 | 0.16 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 60.22 | 74.47 |
Silvercrest Asset Management Group Inc is a wealth management firm focused on providing financial advisory and related family office services to ultra-high net-worth individuals and institutional investors. It advises clients on traditional investment strategies focused on equities, fixed income and cash as well as non-traditional investment strategies including hedge funds, private equity funds, real estate and commodities. It also provides clients with family office services and related administrative services, which include financial planning, tax planning and preparation, partnership accounting and fund administration, and consolidated wealth reporting. The company derives revenues principally from assets under management.
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.